IQVIA HoldingsIQV

UBS set a price target of $345 for the stock this week, which is significantly higher than where it currently trades around $259. Earlier in the week, Truist Financial also raised its own target to $329. These moves suggest analysts see more value in the company's massive backlog of drug-research contracts than the broader market currently does.

Source: UBS

On September 23, IQVIA completed a sale of 2 billion dollars in new debt due in 2034. The company will use the cash to pay off its 5 percent notes that were set to expire in 2026 and to pay down part of its revolving credit facility, which acts like a corporate credit card for short-term needs.

While the new debt carries a higher interest rate than the notes it is replacing, this move clears out a large payment that was due soon. For a company with a high debt load, pushing these deadlines further into the future is a routine way to keep its finances stable and ensure it has enough cash on hand to run its clinical trial and data business.

Source: 8-K filing

Morgan Stanley analysts raised their price target for the stock to $270 from $240 on Thursday. The firm kept its rating at a neutral level, which means they expect the stock to perform about the same as the broader market. This target is slightly above the average analyst target of $246. It suggests the firm sees the stock as fairly valued at its current price near $268, rather than having significant room to run from here.

Source: Morgan Stanley

IQVIA is raising 2 billion dollars through a new bond sale. These bonds, which are basically IOUs to investors, will not come due until 2034. The company plans to use the cash to pay off older debt that was set to expire this year and to pay down its credit card-like revolving loan facility.

This is a routine move to manage its high debt levels. By swapping debt that is due now for debt that isn't due for eight years, the company buys itself more time and keeps its cash flow flexible for its research and data business. It does not change the total amount the company owes, but it ensures they aren't facing a large cash squeeze in the near term.

Source: Business Wire

Running clinical trials is the most expensive and time-consuming part of bringing a new drug to market. IQVIA launched a new system this week that uses artificial intelligence to analyze patient data and trial designs, which it says can help drugmakers finish their research up to two years faster than usual.

This matters because IQVIA's main business is helping pharmaceutical companies run these trials. If it can use software to cut years off the process, it becomes a much more valuable partner to drugmakers who are racing to get their products approved before patents expire. It also helps IQVIA's own profit margins, as software-driven work is generally cheaper to perform than manual research.

Source: Business Wire

Metrics we are tracking